Astrazeneca (AZN) Stock Price, News & Analysis

Company Overview

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology. Well-known marketed products include Tagrisso (osimertinib) and Imfinzi (durvalumab) in oncology, Lynparza (olaparib) developed in partnership for certain cancer indications, Farxiga (dapagliflozin) for diabetes and heart failure, and Brilinta (ticagrelor) in cardiology. AstraZeneca also collaborated with the University of Oxford to develop the Vaxzevria COVID-19 vaccine. Beyond marketed drugs, AstraZeneca pursues strategic partnerships, licensing and acquisitions to expand its scientific and commercial reach.

AstraZeneca operates commercially and conducts clinical research around the world, with significant commercial presence in the United States, Europe, China and emerging markets. Its operations encompass global manufacturing and supply chains, clinical trial networks, and collaborations with academic institutions and biotech companies. The company frequently engages with regulators in major markets to obtain approvals and manage post-approval commitments.

Leadership has emphasized a long-term focus on innovation and targeted investment in specific therapeutic areas; Pascal Soriot has served as chief executive officer, overseeing strategy that prioritizes oncology and cardiometabolic research while building a diversified pipeline. AstraZeneca’s business model centers on discovery-led development, strategic alliances and global commercialization to deliver prescription medicines to patients worldwide.

Key Stats

• Today's Range: $181.73 to $185.81
• 50-Day Range: $181.36 to $205.03
• 52-Week Range: $132.32 to $212.71
• Volume: 2.09 million shs
• Average Volume: 2.73 million shs
• Market Capitalization: $282.13 billion
• P/E Ratio: 27.31
• Dividend Yield: 2.39%
• Price Target: $205.33
• Consensus Rating: Moderate Buy

Astrazeneca Stock Analysis - MarketRank™

Astrazeneca scored higher than 85% of companies evaluated by MarketBeat, and ranked 9th out of 57 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Astrazeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Astrazeneca has a consensus price target of $205.33, representing about 12.9% upside from its current price of $181.91.

Amount of Analyst Coverage

Astrazeneca has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.57%

Earnings Growth

Earnings for Astrazeneca are expected to grow by 12.57% in the coming year, from $10.26 to $11.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astrazeneca is 27.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.43.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astrazeneca is 27.31, which means that it is trading at a more expensive P/E ratio than the Manufacturing sector average P/E ratio of about 23.54.

Price to Earnings Growth Ratio

Astrazeneca has a PEG Ratio of 1.50. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Astrazeneca has a P/B Ratio of 5.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.12% of the float of Astrazeneca has been sold short.

Short Interest Ratio / Days to Cover

Astrazeneca has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Astrazeneca has recently increased by 5.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Astrazeneca pays a meaningful dividend of 2.37%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Astrazeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Astrazeneca is 65.17%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Astrazeneca will have a dividend payout ratio of 37.58% next year. This indicates that Astrazeneca will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.24

News Sentiment

Astrazeneca has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Astrazeneca this week, compared to 9 articles on an average week.

Search Interest

16 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

12 people have added Astrazeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astrazeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

20.35% of the stock of Astrazeneca is held by institutions.

Company Calendar

• Record date for 3/23 Dividend: 2/20/2026
• Ex-Dividend for 3/23 Dividend: 2/20/2026
• Dividend Payable: 3/23/2026
• Last Earnings: 4/29/2026
• Today: 5/11/2026
• Next Earnings (Estimated): 7/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:AZN
• Previous Symbol: NASDAQ:AZN
• CIK: 901832
• Web: N/A
• Phone: 011 44 20 7304 5000
• Fax: 44-12-2335-2858
• Employees: 96,100
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Astrazeneca: $205.33
• High Price Target: $216.00
• Low Price Target: $194.00
• Potential Upside/Downside: +12.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.66
• Trailing P/E Ratio: 27.31
• Forward P/E Ratio: 17.73
• P/E Growth: 1.5
• Net Income: $10.23 billion
• Net Margins: 17.19%
• Pretax Margin: 21.37%
• Return on Equity: 30.86%
• Return on Assets: 12.68%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 0.91
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $58.74 billion
• Price / Sales: 4.80
• Cash Flow: $12.87 per share
• Price / Cash Flow: 14.14
• Book Value: $31.41 per share
• Price / Book: 5.79

Miscellaneous

• Outstanding Shares: 1,550,910,000
• Free Float: N/A
• Market Cap: $282.13 billion
• Optionable: N/A
• Beta: 0.26